Related Experiment Videos
Platelet-derived growth factor(s) mitogenic activity in patients with myeloproliferative disease
Abstract:
Platelet-derived growth factor has been invoked in the pathogenesis of medullary fibrosis during myeloproliferative disorders. In this study we compared the mitogenic activity of heat-stable platelet-growth factor(s) from 13 patients suffering from myeloproliferative disorders with that of a normal group. The test was carried out on Go growth arrested Balb/c 3T3 fibroblasts incubated with various concentrations of platelet extracts, determining the entrance into the S phase by means of [14C]thymidine uptake. The incorporation curves of [14C]thymidine by the fibroblast culture, under the effect of pathological extracts, were consistently lower than the control curve, indicating a lower level of PDGF(s) in platelets from patients. The greatest depression of this activity was found to be associated with highest degree of medullary fibrosis (agnogenic myeloid metaplasia patient group), in agreement with the hypothesis that fibroblast activation within bone marrow during myeloproliferative disorders might be correlated with a PDGF(s) release in the bone marrow environment.
Insights
Platelet-derived growth factor (PDGF) levels are lower in patients with myeloproliferative disorders, correlating with medullary fibrosis. This suggests reduced PDGF activity contributes to bone marrow fibrosis in these conditions.
Area of Science:
- Hematology
- Oncology
- Cell Biology
Background:
- Platelet-derived growth factor (PDGF) is implicated in medullary fibrosis within myeloproliferative disorders.
- Understanding PDGF levels is crucial for elucidating the pathogenesis of bone marrow fibrosis.
Purpose of the Study:
- To compare the mitogenic activity of platelet-derived growth factors (PDGFs) in patients with myeloproliferative disorders versus healthy individuals.
- To investigate the correlation between PDGF activity and the degree of medullary fibrosis.
Main Methods:
- Assessed mitogenic activity of heat-stable PDGFs from 13 myeloproliferative disorder patients and a control group.
- Used Go growth-arrested Balb/c 3T3 fibroblasts incubated with platelet extracts.
- Measured fibroblast entry into S phase via [14C]thymidine uptake.
Main Results:
- Fibroblast [14C]thymidine uptake was consistently lower with pathological platelet extracts compared to controls.
- This indicates reduced levels of PDGF in platelets from myeloproliferative disorder patients.
- The most significant reduction in PDGF activity was observed in patients with the highest degree of medullary fibrosis (agnogenic myeloid metaplasia).
Conclusions:
- Platelet-derived growth factor (PDGF) levels are diminished in patients with myeloproliferative disorders.
- Lower PDGF activity may contribute to the pathogenesis of medullary fibrosis in these conditions.
- Fibroblast activation in bone marrow during myeloproliferative disorders may correlate with PDGF release.